Is LUNG or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Pulmonx's net margin of -55.03%. Electromed's return on equity of 15.71% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% Electromed 11.34% 15.71% 13.37%

Which has better valuation & earnings, LUNG or PDEX?

Pro-Dex has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulmonx $90.50M 0.87 -$54M -$1.16 N/A Pro-Dex $77.55M 2.64 $13.66M $4.13 15.51

Is LUNG or PDEX more profitable?

Pro-Dex has a net margin of 17.62% compared to Pulmonx's net margin of -55.03%. Pro-Dex's return on equity of 25.13% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pulmonx -55.03% -96.66% -38.32% Pro-Dex 17.62% 25.13% 16.02%

Pulmonx (LUNG) Competitors

$1.83 -0.08 (-4.19%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.83 0.00 (0.00%)

As of 10/2/2026 07:50 PM Eastern

Compare

LUNG vs. TMCI, MOBI, TLSI, ELMD, and PDEX

Should you buy Pulmonx stock or one of its competitors? Pulmonx's main competitors and comparable companies include Treace Medical Concepts (TMCI), Mobia Medical (MOBI), TriSalus Life Sciences (TLSI), Electromed (ELMD), and Pro-Dex (PDEX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulmonx compare to Treace Medical Concepts?

Pulmonx (NASDAQ:LUNG) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Pulmonx has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Pulmonx presently has a consensus target price of $7.67, indicating a potential upside of 318.94%. Treace Medical Concepts has a consensus target price of $5.17, indicating a potential upside of 17.77%. Given Pulmonx's stronger consensus rating and higher possible upside, research analysts clearly believe Pulmonx is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Treace Medical Concepts had 4 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for Treace Medical Concepts and 0 mentions for Pulmonx. Treace Medical Concepts' average media sentiment score of 0.63 beat Pulmonx's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Neutral
Treace Medical Concepts	Positive

Treace Medical Concepts has a net margin of -28.99% compared to Pulmonx's net margin of -55.03%. Treace Medical Concepts' return on equity of -71.37% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

Pulmonx has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.87	-$54M	-$1.16	N/A
Treace Medical Concepts	$212.69M	1.34	-$59M	-$0.93	N/A

Summary

Treace Medical Concepts beats Pulmonx on 10 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Mobia Medical?

Mobia Medical (NASDAQ:MOBI) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

91.0% of Pulmonx shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Mobia Medical had 1 more articles in the media than Pulmonx. MarketBeat recorded 1 mentions for Mobia Medical and 0 mentions for Pulmonx. Mobia Medical's average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score.

Company	Overall Sentiment
Mobia Medical	Neutral
Pulmonx	Neutral

Mobia Medical has a net margin of 0.00% compared to Pulmonx's net margin of -55.03%. Mobia Medical's return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mobia Medical	N/A	N/A	N/A
Pulmonx	-55.03%	-96.66%	-38.32%

Mobia Medical has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mobia Medical	$45.28M	6.75	-$46.50M	-$20.18	N/A
Pulmonx	$90.50M	0.87	-$54M	-$1.16	N/A

Mobia Medical presently has a consensus price target of $20.75, indicating a potential upside of 126.03%. Pulmonx has a consensus price target of $7.67, indicating a potential upside of 318.94%. Given Pulmonx's higher possible upside, analysts clearly believe Pulmonx is more favorable than Mobia Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mobia Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Mobia Medical beats Pulmonx on 9 of the 14 factors compared between the two stocks.

How does Pulmonx compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

TriSalus Life Sciences has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

TriSalus Life Sciences currently has a consensus target price of $10.20, suggesting a potential upside of 136.11%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 318.94%. Given Pulmonx's stronger consensus rating and higher possible upside, analysts plainly believe Pulmonx is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 7.5% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, TriSalus Life Sciences had 3 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 0 mentions for Pulmonx. TriSalus Life Sciences' average media sentiment score of 0.24 beat Pulmonx's score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
TriSalus Life Sciences	Neutral
Pulmonx	Neutral

Pulmonx has a net margin of -55.03% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
Pulmonx	-55.03%	-96.66%	-38.32%

TriSalus Life Sciences has higher earnings, but lower revenue than Pulmonx. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	5.89	-$39.23M	-$1.30	N/A
Pulmonx	$90.50M	0.87	-$54M	-$1.16	N/A

Summary

Pulmonx beats TriSalus Life Sciences on 8 of the 15 factors compared between the two stocks.

How does Pulmonx compare to Electromed?

Pulmonx (NASDAQ:LUNG) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Pulmonx has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Electromed has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

In the previous week, Electromed had 1 more articles in the media than Pulmonx. MarketBeat recorded 1 mentions for Electromed and 0 mentions for Pulmonx. Electromed's average media sentiment score of 1.84 beat Pulmonx's score of 0.00 indicating that Electromed is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Neutral
Electromed	Very Positive

Electromed has a net margin of 11.34% compared to Pulmonx's net margin of -55.03%. Electromed's return on equity of 15.71% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
Electromed	11.34%	15.71%	13.37%

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 10.5% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pulmonx currently has a consensus price target of $7.67, suggesting a potential upside of 318.94%. Electromed has a consensus price target of $43.75, suggesting a potential upside of 55.69%. Given Pulmonx's higher possible upside, equities analysts plainly believe Pulmonx is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Electromed has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.87	-$54M	-$1.16	N/A
Electromed	$73.78M	3.19	$5.15M	$1.31	21.45

Summary

Electromed beats Pulmonx on 11 of the 14 factors compared between the two stocks.

How does Pulmonx compare to Pro-Dex?

Pulmonx (NASDAQ:LUNG) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Pro-Dex's average media sentiment score of 1.00 beat Pulmonx's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulmonx	Neutral
Pro-Dex	Positive

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pro-Dex has a net margin of 17.62% compared to Pulmonx's net margin of -55.03%. Pro-Dex's return on equity of 25.13% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-55.03%	-96.66%	-38.32%
Pro-Dex	17.62%	25.13%	16.02%

Pulmonx presently has a consensus target price of $7.67, suggesting a potential upside of 318.94%. Pro-Dex has a consensus target price of $74.00, suggesting a potential upside of 15.50%. Given Pulmonx's higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Pulmonx has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market.

Pro-Dex has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.87	-$54M	-$1.16	N/A
Pro-Dex	$77.55M	2.64	$13.66M	$4.13	15.51

Summary

Pro-Dex beats Pulmonx on 10 of the 15 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$78.59M	$5.43B	$7.14B	$13.22B
Dividend Yield	N/A	1.80%	2.53%	16.78%
P/E Ratio	N/A	24.90	275.97	26.04
Price / Sales	0.87	84.37	672.86	109.50
Price / Cash	N/A	32.43	77.60	51.75
Price / Book	1.40	5.73	10.93	6.31
Net Income	-$54M	$152.68M	$3.51B	$362.16M
7 Day Performance	-4.19%	-1.71%	-2.00%	-1.66%
1 Month Performance	-19.03%	-4.81%	-6.15%	-4.50%
1 Year Performance	-0.54%	1.08%	7.44%	2.06%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	3.3121 of 5 stars	$1.83 -4.2%	$7.67 +318.9%	+8.3%	$78.59M	$90.50M	N/A	296
TMCI Treace Medical Concepts	2.8223 of 5 stars	$4.47 -0.2%	$5.17 +15.6%	-29.9%	$291.05M	$212.69M	N/A	450
MOBI Mobia Medical	3.2528 of 5 stars	$8.67 -4.3%	$20.75 +139.3%	N/A	$288.62M	$32.04M	N/A	167	Gap Down
TLSI TriSalus Life Sciences	2.6081 of 5 stars	$4.31 -1.8%	$10.20 +136.7%	-4.4%	$265.47M	$45.15M	N/A	102
ELMD Electromed	3.1219 of 5 stars	$27.83 -1.2%	$43.75 +57.2%	+13.7%	$232.78M	$73.78M	37.10	197	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors

LUNG vs. TMCI, MOBI, TLSI, ELMD, and PDEX

How does Pulmonx compare to Treace Medical Concepts?

Summary

How does Pulmonx compare to Mobia Medical?

Summary

How does Pulmonx compare to TriSalus Life Sciences?

Summary

How does Pulmonx compare to Electromed?

Summary

How does Pulmonx compare to Pro-Dex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Competitors

LUNG vs. TMCI, MOBI, TLSI, ELMD, and PDEX

How does Pulmonx compare to Treace Medical Concepts?

Which has more volatility and risk, LUNG or TMCI?

Do analysts prefer LUNG or TMCI?

Do institutionals & insiders have more ownership in LUNG or TMCI?

Does the media favor LUNG or TMCI?

Is LUNG or TMCI more profitable?

Which has higher earnings and valuation, LUNG or TMCI?

Summary

How does Pulmonx compare to Mobia Medical?

Do institutionals & insiders have more ownership in MOBI or LUNG?

Does the media favor MOBI or LUNG?

Is MOBI or LUNG more profitable?

Which has stronger earnings & valuation, MOBI or LUNG?

Do analysts recommend MOBI or LUNG?

Summary

How does Pulmonx compare to TriSalus Life Sciences?

Which has more volatility and risk, TLSI or LUNG?

Do analysts prefer TLSI or LUNG?

Do insiders and institutionals hold more shares of TLSI or LUNG?

Does the media prefer TLSI or LUNG?

Is TLSI or LUNG more profitable?

Which has preferable earnings and valuation, TLSI or LUNG?

Summary

How does Pulmonx compare to Electromed?

Which has more volatility and risk, LUNG or ELMD?

Does the media refer more to LUNG or ELMD?

Is LUNG or ELMD more profitable?

Do insiders and institutionals believe in LUNG or ELMD?

Do analysts prefer LUNG or ELMD?

Which has stronger valuation and earnings, LUNG or ELMD?

Summary

How does Pulmonx compare to Pro-Dex?

Does the media refer more to LUNG or PDEX?

Do insiders & institutionals hold more shares of LUNG or PDEX?

Is LUNG or PDEX more profitable?

Do analysts recommend LUNG or PDEX?

Which has more risk and volatility, LUNG or PDEX?

Which has better valuation & earnings, LUNG or PDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools